Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of anlotinib hydrochloride capsules in radioactive iodine-refractory locally advanced or metastatic differentiated thyroid cancer
CTR20243692Phase 4Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of anlotinib in well-differentiated thyroid cancer (WDTC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jan 2024; status: active.
02
Drugs
anlotinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20243692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243692.